恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议_老虎社区_美港股上老虎

恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议

21世纪经济报道05-13

政策动向　　国家药监局局长黄果会见新加坡卫生科学局局长蔡瑞文双方就创新医疗器械等议题深入交换意见　　国家药监局局长黄果5月11日在京会见了来访的新加坡卫生科学局局长蔡瑞文一行，并签署《中华人民共和国国家药品监督管理局与新加坡共和国卫生科学局监管合作谅解备忘录》。双方就细胞和基因治疗、创新医疗器械及人工智能产品监管等议题深入交换意见。双方同意，以本次签署合作谅解备忘录为里程碑，强化合作机制，细化...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2635221419?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-13 08:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635221419","market":"us","top_or_hot":-1,"title":"恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议","media":"21世纪经济报道","content":"<div>\n<p>政策动向　　国家药监局局长黄果会见新加坡卫生科学局局长蔡瑞文双方就创新医疗器械等议题深入交换意见　　国家药监局局长黄果5月11日在京会见了来访的新加坡卫生科学局局长蔡瑞文一行，并签署《中华人民共和国国家药品监督管理局与新加坡共和国卫生科学局监管合作谅解备忘录》。双方就细胞和基因治疗、创新医疗器械及人工智能产品监管等议题深入交换意见。双方同意，以本次签署合作谅解备忘录为里程碑，强化合作机制，细化...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202605133735150673.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-13 08:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202605133735150673.html><strong>21世纪经济报道</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>政策动向　　国家药监局局长黄果会见新加坡卫生科学局局长蔡瑞文双方就创新医疗器械等议题深入交换意见　　国家药监局局长黄果5月11日在京会见了来访的新加坡卫生科学局局长蔡瑞文一行，并签署《中华人民共和国国家药品监督管理局与新加坡共和国卫生科学局监管合作谅解备忘录》。双方就细胞和基因治疗、创新医疗器械及人工智能产品监管等议题深入交换意见。双方同意，以本次签署合作谅解备忘录为里程碑，强化合作机制，细化...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202605133735150673.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0203345920.USD","symbol_name":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202605133735150673.html","article_id":"2635221419","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605133735150673.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635221419","pubTimestamp":1778630577,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"政策动向国家药监局局长黄果会见新加坡卫生科学局局长蔡瑞文双方就创新医疗器械等议题深入交换意见国家药监局局长黄果5月11日在京会见了来访的新加坡卫生科学局局长蔡瑞文一行，并签署《中华人民共和国国家药品监督管理局与新加坡共和国卫生科学局监管合作谅解备忘录》。双方就细胞和基因治疗、创新医疗器械及人工智能产品监管等议题深入交换意见。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"301206":"三元生物","600276":"恒瑞医药","688506":"百利天恒","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU0359201612.USD":"贝莱德中国基金A2","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","MRK":"默沙东","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU0861579265.USD":"联博低波幅策略股票基金A","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4007":"制药","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0183":"MSCI概念","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4550":"红杉资本持仓","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0028":"国家队","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK1191":"制药","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999002232.USD":"Allianz Global High Payout USD","BK0060":"抗癌","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","002022":"科华生物","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","BK4534":"瑞士信贷持仓","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK0239":"医药制造","BK0012":"证金概念","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","BK4516":"特朗普概念","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","01276":"恒瑞医药","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","BK0188":"融资融券","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK4585":"ETF&股票定投概念","BK0196":"行业龙头","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU1146622755.USD":"安本中国A股股票基金A Acc","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK4559":"巴菲特持仓","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","BK4588":"碎股"},"translate_title":"Hengrui Medicine and BMS set a new cooperation record; Merck signed agreements with a number of pharmaceutical companies","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"301206":1.86,"600276":1.95,"688506":1.9,"01276":1.95,"002022":1.93,"MRK":1.91},"content_text":"政策动向　　国家药监局局长黄果会见新加坡卫生科学局局长蔡瑞文双方就创新医疗器械等议题深入交换意见　　国家药监局局长黄果5月11日在京会见了来访的新加坡卫生科学局局长蔡瑞文一行，并签署《中华人民共和国国家药品监督管理局与新加坡共和国卫生科学局监管合作谅解备忘录》。双方就细胞和基因治疗、创新医疗器械及人工智能产品监管等议题深入交换意见。双方同意，以本次签署合作谅解备忘录为里程碑，强化合作机制，细化时间表、路线图，深化信息共享、审评协同、技术交流，推进监管互信和提质增效，共同推动两国及地区监管发展，守护公众健康。　　药械审批　　科华生物：控股子公司全自动核酸分析系统获医疗器械注册证　　科华生物(002022.SZ)公告称，公司控股子公司西安天隆科技的全自动核酸纯化及扩增检测分析系统获得国家药监局颁发的医疗器械注册证，有效期至2031年5月10日。该产品基于磁珠法核酸提取和实时荧光PCR检测原理，用于人体样本中靶核酸的定性、定量检测，包括病原体和人类基因检测项目。此次注册证取得将丰富公司产品线，对业务发展有正面影响，但具体营收影响尚无法预测。　　百奥泰：注射用BAT8013获临床试验批准　　5月12日，百奥泰公告，注射用BAT8013收到国家药品监督管理局《药物临床试验批准通知书》（受理号：CXSL2600298），同意该药单药在晚期或转移性实体瘤患者中开展临床试验。该药为靶向CD25的抗体药物偶联物（ADC），拟通过清除肿瘤微环境中调节性T细胞并直接杀伤CD25阳性肿瘤细胞，发挥抗肿瘤作用。　　百利天恒：注射用T-Bren用于一线HER2阳性乳腺癌III期临床试验完成首例受试者入组　　百利天恒(688506.SH)公告称，公司自主研发的创新生物药注射用T-Bren(HER2ADC)联合帕妥珠单抗和曲妥珠单抗对比帕妥珠单抗联合多西他赛用于一线HER2阳性的复发或转移性乳腺癌III期临床试验已完成首例受试者入组。截至目前，T-Bren正在国内外开展17项临床试验，覆盖乳腺癌、胃癌、非小细胞肺癌等多种适应症。　　行业大事　　恒瑞医药：与百时美施贵宝公司签署战略合作及许可协议　　恒瑞医药12日午间公告，公司与百时美施贵宝公司（简称“BMS”）达成全球战略合作及许可协议，共同推进13款涵盖肿瘤学、血液学及免疫学的早期项目，以加速创新药物研发，惠及全球患者。根据协议，BMS将向恒瑞支付可达9.5亿美元的相关付款，即6亿美元首付款、第一笔周年付款1.75亿美元，以及第二笔有条件的2028年周年付款1.75亿美元。协议的潜在总交易额可达约152亿美元（包括共同研发项目选择权的行使，以及所有项目达成相应的开发、注册及商业化里程碑）。　　21点评：此次恒瑞与BMS达成深度合作，离不开恒瑞强大的模块化开发能力、庞大且高效的专业临床执行团队，以及丰富的临床管线。这一系列优势的背后，是恒瑞多年前就开始的研发战略持续投入，加上其在BD（商务拓展）领域一贯的灵活策略。　　默沙东与美赛生物、达歌生物签署合作协议共同推进临床合作开发　　默沙东研发（中国）有限公司宣布，已分别与美赛生物、达歌生物签署合作协议，各方将基于独立合作框架，共同推进临床合作开发；并与泽璟制药、益方生物签署合作意向书。本轮合作聚焦肿瘤及自身免疫疾病等治疗领域：默沙东将与美赛生物在自身免疫疾病领域开展抗体药物的临床开发，与达歌生物聚焦肿瘤领域分子胶药物的临床开发。　　资本市场　　星锐医药完成2.7亿元B+轮融资　　5月11日消息，星锐医药宣布完成近4000万美元（约 2.7 亿元）B+轮融资。本轮融资由知名产业基金联合高瓴创投、LYFE Capital (洲岭资本）、礼来亚洲基金（LAV)、夏尔巴投资、源码资本及春华资本共同参投。　　信立泰：股价连续三个交易日跌幅累计超20% 不存在应披露而未披露的重大事项　　5月12日，信立泰发布异动公告称，公司股票连续三个交易日内日收盘价格跌幅偏离值累计超过20%，属于股票交易异常波动的情况。公司前期披露的信息不存在需要更正、补充之处。公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大影响的未公开重大信息。公司目前经营状况良好，外部市场环境、行业政策、公司基本面等未发生重大变化。公司、控股股东和实际控制人不存在关于公司的应披露而未披露的重大事项，或处于筹划阶段的重大事项。　　舆情预警　　三元生物：持股5%以上股东减持100万股　　5月12日，三元生物公告称，持股5%以上股东吕熙安于2026年5月6日至11日通过集中竞价方式累计减持公司股份100万股，占公司当前总股本（剔除回购专用证券账户股份）的0.5%。（文章来源：21世纪经济报道）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}